Lung Cancer Dispatch
Follow
Find tag "Abraxane"
3.9K views | +0 today
Lung Cancer Dispatch
News for Patients and Physicians
Curated by Cancer Commons
Your new post is loading...
Your new post is loading...
Suggested by Cancer Commons
Scoop.it!

Novel Immune-Based Cancer Drug Imprime PGG Appears Effective in Certain Lung Cancer Patients

Novel Immune-Based Cancer Drug Imprime PGG Appears Effective in Certain Lung Cancer Patients | Lung Cancer Dispatch | Scoop.it

Adding the drug Imprime PGG to chemotherapy and antibody therapy may be effective for certain patients with non-small cell lung cancer (NSCLC). Imprime PGG contains a molecule called beta glucan, which can stimulate the body’s immune cells to destroy cancer cells. This process may be especially effective in patients with high levels of immune system proteins that bind to beta glucan, so-called antibeta glucan antibodies. In a recent clinical trial, patients with advanced NSCLC received the antibody drug cetuximab (Erbitux) and the chemotherapy agents carboplatin (Paraplatin) and paclitaxel (Taxol/Abraxane), and some were also given Imprime PGG. While survival across all patients was not affected by Imprime PGG treatment, it was increased in Imprime PGG-treated patients with high levels of antibeta glucan antibodies. Seventeen percent of these patients survived 3 years or more, while none of the other patient groups did.

Cancer Commons's insight:

Medical Xpress  |  Jan 8, 2014

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

Erbitux-Avastin Combination Plus Chemotherapy in Lung Cancer Is Safe and Effective

Erbitux-Avastin Combination Plus Chemotherapy in Lung Cancer Is Safe and Effective | Lung Cancer Dispatch | Scoop.it

Combining cetuximab (Erbitux), bevacizumab (Avastin), and traditional chemotherapy in patients with non-small cell lung cancer (NSCLC) appeared to be safe and effective in a phase II clinical trial. Patients with advanced non-squamous NSCLC received Erbitux and Avastin in addition to carboplatin (Paraplatin) and paclitaxel (Taxol/Abraxane) as first-line treatment, followed by maintenance treatment with Erbitux and Avastin. Tumors shrank in 56% of patients and stopped growing in an additional 21%. Serious side effects were relatively rare; the rate was comparable to that of either Erbitux or Avastin alone. Both Erbitux and Avastin have shown efficacy in NSCLC by themselves, but may be more effective when given together. An ongoing phase III clinical trial will further investigate this drug combination.

Cancer Commons's insight:

Medical News Today | Nov 5, 2013

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

New Cancer Drug Reolysin Shrinks Lung Tumors

Interim results from a phase II clinical trial of the new cancer drug Reolysin in squamous cell carcinoma (SCC) of the lung, a type of non-small cell lung cancer (NSCLC), show that tumors shrank in 23 of 25 patients. The patients had SCC that had spread from its original site, or recurred after treatment, and were treated with the chemotherapy drugs Paraplatin (carboplatin) and Taxol/Abraxane (paclitaxel) in addition to Reolysin. Ten patients experienced tumor shrinkage and 13 experienced stable disease, while the cancer progressed in 2 patients. On average, tumors shrank by a third of their original size. Reolysin consists of a modified form of a virus that selectively attacks cancer cells, while producing no symptoms in most healthy people.

Cancer Commons's insight:

Businessweek | Sep 9, 2013

more...
No comment yet.
Rescooped by Cancer Commons from Melanoma Dispatch
Scoop.it!

First Treatment for Pain Caused by Chemotherapy

First Treatment for Pain Caused by Chemotherapy | Lung Cancer Dispatch | Scoop.it

Conventional chemotherapy can damage nerves, causing pain and numbness, particularly in the hands and feet. Called neuropathy, this side effect can last months or even years after the completion of chemotherapy and there are currently no effective treatments. A new JAMA study shows that chemotherapy-induced neuropathy can be lessened with a drug called duloxetine (Cymbalta), which has also been shown to alleviate neuropathy in people with diabetes. The new study included 231 people who reported pain of at least 4 (on a scale of 0 to 10) after treatment with oxaliplatin or taxanes such as paclitaxel. Nearly 60% of those treated with duloxetine reported pain relief and those who had been treated with oxaliplatin may have benefited the most.



Cancer Commons's insight:

Medical Express│Apr 2, 2013

more...
Cancer Commons's curator insight, April 2, 2013 10:43 PM

Medical Xpress│Apr 2, 2013

Cancer Commons's curator insight, April 3, 2013 2:23 PM

Medical Express│Apr 2, 2013

Suggested by Cancer Commons
Scoop.it!

CHFR Protein Levels Predict Effectiveness of Chemotherapy

CHFR Protein Levels Predict Effectiveness of Chemotherapy | Lung Cancer Dispatch | Scoop.it

A study of patients with advanced non-small cell lung cancer (NSCLC) given chemotherapy with carboplatin (Paraplatin) and paclitaxel (Taxol or Abraxane) found that patients with lower levels of the protein CHFR were more likely to respond to the treatment and survived longer than patients with high CHFR levels. These findings suggest that CHFR levels could be a useful biomarker for indicating patients likely to respond to so-called taxane chemotherapy drugs like Taxol, Abraxane, or docetaxel (Taxotere). In the future, treatments that target CHFR may be developed to increase responsiveness to taxane chemotherapy in patients with high CHFR levels.

Cancer Commons's insight:

Clinical Cancer Research | Feb 5, 2013

more...
No comment yet.
Scooped by Cancer Commons
Scoop.it!

FDA Approves Abraxane for Treatment of Advanced NSCLC

FDA Approves Abraxane for Treatment of Advanced NSCLC | Lung Cancer Dispatch | Scoop.it

The FDA has approved the use of breast cancer drug Abraxane in conjunction with carboplatin for non-small cell lung cancer (NSCLC) treatment. Abraxane, manufactured by Celgene Corp., combines paclitaxel with a protein called albumin. Earlier this year, a large clinical trial found Abraxane plus carboplatin to be more effective in shrinking advanced NSCLC tumors than the standard paclitaxel drug Taxol plus carboplatin. Abraxane treatment may be particularly effective for patients with squamous NSCLC patients age 70 years or older and North American patients.

Cancer Commons's insight:

Huffington Post | Oct 12, 2012

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

Four-Drug Combination Shown to Be Safe and Effective for NSCLC

Four-Drug Combination Shown to Be Safe and Effective for NSCLC | Lung Cancer Dispatch | Scoop.it

A combination of the drugs carboplatin (Paraplatin), paclitaxel (Taxol/Abraxane), cetuximab (Erbitux), and bevacizumab (Avastin) has demonstrated effectiveness against non-small cell lung cancer (NSCLC) in a phase II clinical trial. One hundred two patients with advanced non-squamous NSCLC received the four-drug combo as a first-line treatment. Tumors shrank in 56% of patients and stopped growing in an additional 21%. Patients went an average of 7 months without their cancer progressing; the average survival time was 15 months. Four treatment-related deaths occurred, including two due to hemorrhage (heavy bleeding), which can be a rare but serious effect of Avastin treatment. This side effect profile was within the predefined safety margin. A phase III trial further investigating this drug combination for NSCLC is currently enrolling participants.

Cancer Commons's insight:

MedwireNews  |  Dec 2, 2013

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

Alimta Offers Only Limited Advantage in Lung Cancer Study

The recent PointBreak clinical trial compared two treatment regimens for non-squamous non-small cell lung cancer (NSCLC). Previously untreated patients with advanced non-squamous NSCLC received initial treatment with carboplatin (Paraplatin), bevacizumab (Avastin), and either pemetrexed (Alimta) or paclitaxel (Taxol/Abraxane). The Alimta-treated group was then given maintenance treatment with Alimta and Avastin, while the other patients received Avastin only. Alimta treatment was associated with slightly longer times until the cancer progressed again (average 6.0 months, compared to 5.6 in the Alimta-free regimen). However, overall survival did not differ between the groups. The two regimens differed in what specific side effect were most common, but had similar overall toxicities and were generally tolerable.

Cancer Commons's insight:

MedPage Today | Oct 21, 2013

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

Comparison of Combination Chemotherapy Regimens Shows No Significant Differences

Both pemetrexed (Alimta) plus carboplatin (Paraplatin) and Paraplatin plus paclitaxel (Taxol/Abraxane) plus bevacizumab (Avastin) are effective chemotherapy regimens against non-small cell lung cancer (NSCLC). However, until recently, the safety and efficacy of the two regimens had not been directly compared. To evaluate whether one regimen was superior, a phase III clinical trial determined how long patients with advanced non-squamous NSCLC remained free of either cancer progression or severe toxic side effects when treated with either of the two regimens. While patients receiving the Alimta plus Paraplatin regimen tended to have slightly longer relapse- and toxicity-free periods than those given Paraplatin plus Taxol/Abraxane plus Avastin, the difference was not very pronounced and could have happened by chance. The two regimens also did not differ regarding overall time until cancer progression, response rate and overall survival time.

Cancer Commons's insight:

CancerNetwork | June 6, 2013

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

Reolysin Shrinks Lung Cancer Tumors in Clinical Trial

A phase II study of the novel cancer treatment Reolysin in 20 patients with advanced squamous cell carcinoma (SCC) of the lung, a type of non-small cell lung cancer, showed a reduction in tumor size in 95% of patients. Patients were given Reolysin in combination with the chemotherapy drugs carboplatin (Paraplatin) and paclitaxel (Taxol or Abraxane); on average, their tumors shrank by about a third. This finding suggests that Reolysin may be useful for presurgical treatment of tumors. Reolysin, made by the company Oncolytics, is a form of a virus called reovirus. Most adults have been exposed to reovirus, which usually does not produce symptoms. However, reovirus selectively infects and kills tumor cells.


Press release: http://www.oncolyticsbiotech.com/news_items/details?press_release_id=1921

Cancer Commons's insight:

Reuters | Feb 8, 2013

more...
No comment yet.
Scooped by Cancer Commons
Scoop.it!

Abraxane-Paraplatin Combination May be Safe and Effective in Elderly Patients with Advanced Lung Cancer

A recent study examined first-line treatment with the chemotherapy agent carboplatin (Paraplatin) combined with either albumin-bound paclitaxel (Abraxane) or standard solvent-based paclitaxel (Taxol) in both elderly and younger patients with advanced non-small cell lung cancer (NSCLC). Patients treated with Abraxane/Paraplatin exhibited higher treatment response rates and fewer toxic side effects in both age groups, and elderly patients (age 70+ years) experienced longer periods without cancer progression and longer overall survival with Abraxane/Paraplatin compared to Taxol/Paraplatin treatment. Abraxane plus Paraplatin may constitute a safe, effective first-line treatment for elderly patients with advanced NSCLC, a group that has been traditionally undertreated.


Research paper: http://annonc.oxfordjournals.org/content/24/2/314.long

Cancer Commons's insight:

Annals of Oncology | Nov 2, 2012

more...
No comment yet.